Varsal Tech, Inc.
VAT · NYSE American · Materials
- Expected pricing
- Jul 1, 2026
- Price range
- Not yet set
- Shares offered
- —
- Filing
- S-1/A · Jul 1, 2026
Founders & leadership
Background and track record, from the Management section.
- Dr. Pingxin WangFounder, Chairman, Chief Executive Officer
Founder of Varsal LLC in 1993; has served as CEO and Chairman since October 2025. Previously a Researcher at National Medical Services. Holds a PhD in Chemistry from the University of Texas at Austin.
Source
“Dr. Pingxin Wang is the founder of Varsal LLC and has served as our Chief Executive Officer and our Chairman of the Board of Directors since October 2025.”
High confidenceView in filing → - Dongwei WangInterim Chief Financial Officer, Director
Has served as General Manager of Varsal LLC since 2019 and Interim CFO since October 2025. Previously worked at Blackstone in M&A (2010-2013) and Arsenal Capital Partners (2013-2016). Holds BBA from Emory University and MBA from China Europe International Business School.
Source
“Dongwei Wang has served as General Manager of Varsal LLC since 2019 and has served as our interim Chief Financial Officer since October 2025, where he is responsible for financial and operational leadership across the organization.”
High confidenceView in filing → - Kenneth D. FedermanDirector nominee
Founding partner of Rothberg, Federman & Hollister since January 1998, specializing in transactional business, real estate, and commercial litigation. Former Audit Supervisor at Laventhol & Horwath CPA's and former VP of Finance at Jules Jurgensen/Rhapsody, Inc. and Trope Inc.
Source
“Kenneth D. Federman, Esq., will serve as an independent director upon the effectiveness of the registration statement of which this prospectus is a part. Mr. Federman is a founding partner of Rothberg, Federman & Hollister since January 1998.”
High confidenceView in filing → - Jerry LewinDirector nominee
Senior VP of Field Profitability Globally at Hyatt Hotels Corporation since January 2015; previously SVP of Field Operations at Hyatt from 2000-2014. Has been with Hyatt since 1987.
Source
“Jerry Lewin will serve as an independent director upon the effectiveness of the registration statement of which this prospectus is a part. Mr. Lewin has been the Senior Vice President of Field Profitability Globally at Hyatt Hotels Corporation, leading initiatives to enhance operational performance across Hyatt's global portfolio, since January 2015.”
High confidenceView in filing → - George LovasDirector nominee
Vice President at Jefferies Bank since September 2022; previously a consultant at Jefferies Bank (2021-2022) and Chief Risk Officer at Innovating Capital (2019-2021). Earlier worked as a consultant in Mortgage Analytics at Morgan Stanley.
Source
“George Lovas will serve as an independent director upon the effectiveness of the registration statement of which this prospectus is a part. Mr. Lovas has been a Vice President at Jefferies Bank since September 2022.”
High confidenceView in filing →
What the company does
The problem it solves and how it differentiates.
Varsal Tech is a global provider of specialty chemicals, pharmaceutical intermediates, and electronic chemicals, serving customers in pharmaceuticals, electronics, industrials, and personal care. The company develops proprietary chemical processes and provides customized intermediates through a network of third-party manufacturers in China, offering customers fully integrated development, manufacturing, quality assurance, packaging, and logistics services. Its differentiation rests on proprietary process know-how, ISO 9001:2015 and GMP-compliant manufacturing, high switching costs from regulatory qualification requirements, and a capital-efficient model where the company retains ownership of all IP developed through its manufacturing partnerships.
Source
“We develop and supply ISO-certified and GMP-compliant chemicals, intermediates and other customized product solutions supported by proprietary know-how and deep domain and product expertise. Through decades of technological development, we have established a business that serves a diversified and global customer base in the pharmaceutical, electronics, industrial, personal care and research markets.”
Market & competition
The market it plays in and who it competes with.
The company operates in the global specialty and custom chemicals market, targeting pharmaceutical, personal care, electronics, and specialty industrial segments. The specialty chemicals market for pharmaceutical applications was valued at approximately $77 billion in 2024, for electronics approximately $86 billion in 2024, and for consumer goods/personal care/home applications approximately $120 billion in 2024.
Source
“According to reportsanddata.com, the market size for specialty chemicals used in pharmaceutical applications was valued at approximately $77 billion in 2024 and expected to grow at 4.2% CAGR from 2024 – 2034. The market size for specialty chemicals used in electronics was valued at approximately $86 billion in 2024 and is expected to grow at 6.5% CAGR from 2024 – 2034. The market size for specialty chemicals used in consumer goods, personal care and home applications was valued at approximately US$120 billion in 2024 and is expected to grow at 3.6% CAGR through 2034.”
Financials
Revenue, profitability, and cash, from the financial statements.
- Net income
- $7.1M net income (Year ended September 30, 2025)
- Cash & equivalents
- $5.2M (as of March 31, 2026)
- Burn rate
- $7.4M operating cash flow (Year ended September 30, 2025)
Source
“Net income $ 7,113,972”
Source
“Cash and cash equivalents $ 5,246,195”
Source
“Net cash provided by operating activities 7,414,798”
Statement-derived (Year ended September 30, 2025; figures in ones).
The offering
Use of proceeds, pricing, and dilution to new investors.
- fund working capital and other general corporate purposes
- approximately $15 million for future acquisition opportunities for businesses with manufacturing facilities in the United States (specialty chemicals sector, vertical integration for sulfur-based product lines)
- approximately $15 million for greenfield manufacturing plant development in the Middle East (e.g. Saudi Arabia)
Source
“We plan to use the net proceeds we receive from this offering to fund working capital and for other general corporate purposes, including the support of our current business and: approximately $15 million for future acquisition opportunities for businesses with manufacturing facilities in the United States... and approximately $15 million for greenfield manufacturing plant development in the Middle East, (e.g. Saudi Arabia).”
Control & governance
Share classes, founder voting control, board, and insider conflicts — the founder-control signals.
- Class A Common Stock1 vote/share
- Class B Common Stock10 votes/share
5 directors · 3 independent · Chair is also the CEO
Concentrated dependence on a single leader, flagged in the filing.
Source
“We depend on key personnel, particularly our founders and technical experts, partners, and manufacturers, with the loss of key personnel potentially causing harm to our business.”
Lock-up schedule & insider ownership
When insider shares unlock, and who holds them — the part most tools skip.
Lock-up schedule
When insider shares unlock signals when selling pressure may arrive. Conditional unlocks have no fixed date and are shown as such — they are not collapsed to a single guessed date.
- Officers, directors, and holders of substantially all Common Stock and options/convertible securities holdersShare count not disclosedNo fixed dateFixed date
for a period of 180 days after the date of this prospectus
Source
“We, our officers, directors, and holders of substantially all of our Common Stock and any options exercisable for, or securities convertible into, our Common Stock, intend to enter into lock-up agreements with the underwriters, pursuant to which each of these persons or entities, subject to certain limited exceptions, for a period of 180 days after the date of this prospectus, agree that they will not, and shall not cause or direct any of their respective affiliates to (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company (the "Lock-Up Securities")”
High confidenceView in filing → - Officers, directors, and holders of substantially all Common Stock (at Representative's discretion)Share count not disclosedNo fixed dateDiscretionary
The terms of the lock-up agreements may be waived at the Representative's discretion
Source
“The Representative has no present intention to waive or shorten the lock-up period; however, the terms of the lock-up agreements may be waived at its discretion. In determining whether to waive the terms of the lock-up agreements, the Representative may base its decision on its assessment of the relative strengths of the securities markets and companies similar to ours in general, and the trading pattern of, and demand for, our securities in general.”
High confidenceView in filing → - Representative (Underwriter's Warrants)Share count not disclosedNo fixed dateFixed date
180 days from the date of this prospectus (FINRA Rule 5110 lock-up on Underwriter's Warrants)
Source
“The Underwriter's Warrants have been deemed compensation by FINRA and are therefore subject to a six (6) month lock-up pursuant to Rule 5110 of FINRA. The underwriter (or its permitted assignees under the Rule) will not sell, transfer, assign, pledge, or hypothecate the Underwriter's Warrants or the securities underlying the Underwriter's Warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Underwriter's Warrants or the underlying securities for a period of 180 days from the date of this prospectus”
High confidenceView in filing →
Insider ownership
Beneficial ownership as reported in the S-1 (includes shares deemed beneficially owned via options and affiliated entities). Percentages are beneficial, not record, ownership.
| Holder | Shares | % pre-IPO | % post-IPO | Source |
|---|---|---|---|---|
Pingxin Wang Directors and Executive Officers | 15.1K | — | — | Source“Pingxin Wang 15,136 *” High confidenceView in filing → |
Dongwei Wang Directors and Executive Officers | 1.6M | 46.06% | — | Source“Dongwei Wang 1,611,957 46.06 %” High confidenceView in filing → |
Ken Federman Directors and Executive Officers | — | — | — | Source“Ken Federman — —” High confidenceView in filing → |
Jerry Lewin Directors and Executive Officers | — | — | — | Source“Jerry Lewin — —” High confidenceView in filing → |
George Lovas Directors and Executive Officers | — | — | — | Source“George Lovas — —” High confidenceView in filing → |
All directors, nominees and executive officers as a group (5 persons) Directors & executive officers (group) | 1.6M | 46.49% | — | Source“All directors, nominees and executive officers as a group (5 persons) 1,627,093 46.49 %” High confidenceView in filing → |
Huiqin Zhang 5% or greater beneficial owners | 1.5M | 43.25% | — | Source“Huiqin Zhang 1,513,575 43.25 %” High confidenceView in filing → |
James Wang 5% or greater beneficial owners | 217.6K | 6.22% | — | Source“James Wang 217,576 6.22 %” High confidenceView in filing → |
Risk flags
Key items from the Risk Factors section.
- Customer Concentration Risk
Two customers together accounted for 86% of revenue in fiscal year 2025, and a single customer accounted for 83% of revenue in the first half of fiscal 2026; loss of or reduced orders from either customer could materially harm revenue and profitability.
Source
“our two largest customers, Customer B and Customer A, respectively accounted for 45% and 41% of our total revenues”
High confidenceView in filing → - China Manufacturing Concentration
Substantially all products are manufactured at two facilities in China, exposing the company to political instability, regulatory changes, currency risks, tariffs, IP challenges, and supply disruptions.
Source
“Substantially all of our products are manufactured at two facilities in the People's Republic of China (the "PRC") with whom we have had working relationships for many years.”
High confidenceView in filing → - U.S.-China Tariff and Trade Tension Impact
Ongoing U.S.-China tariffs have increased landed costs and logistics complexity; while a temporary reduction is in effect through November 2026, elevated tariffs could be reimposed, reducing price competitiveness and increasing working capital requirements.
Source
“the total landed cost of our products has increased and reduced their price competitiveness relative to domestic or non–U.S. manufactured alternatives.”
High confidenceView in filing → - OFAC Sanctions and PRC Blocking Order Conflict
OFAC has sanctioned PRC-based petrochemical companies, and China's MOFCOM responded with a blocking order prohibiting compliance with those sanctions, creating a direct legal conflict that could impair the company's ability to source products from PRC manufacturers.
Source
“This unprecedented blocking order creates a direct legal conflict between US and Chinese law for companies operating in or sourcing from China, which could impact our operations.”
High confidenceView in filing → - Middle East Geopolitical Risk and Strait of Hormuz Disruption
The February 2026 U.S.-Iran military conflict has led to Strait of Hormuz shipping disruptions, cancelled war-risk insurance, and rising energy costs, which could increase freight costs, raise input costs for PRC manufacturers, and jeopardize the company's planned Middle East expansion.
Source
“On February 28, 2026, the United States and Israel commenced military operations against Iran (Operation Epic Fury)...Iranian forces have declared the Strait of Hormuz 'closed' and have attacked or threatened commercial vessels attempting to transit the Strait.”
High confidenceView in filing → - Material Weakness in Internal Controls
The company identified a material weakness due to limited accounting personnel and inadequate segregation of duties, raising the risk of material misstatements in financial reporting; failure to remediate could lead to restatements, delisting, or regulatory sanctions.
Source
“we concluded that we had limited accounting personnel, and as such, are unable to properly segregate duties.”
High confidenceView in filing → - Dual-Class Share Voting Concentration
Class B Common Stock carries ten votes per share versus one for Class A, concentrating voting control with insiders and potentially delaying or preventing change-of-control transactions that Class A holders might favor.
Source
“holders of our Class B Common Stock will have significant influence over matters submitted to a vote of stockholders, including the election and removal of directors...This concentration of voting power may have the effect of delaying, deterring or preventing a change of control”
High confidenceView in filing → - Key Personnel Dependency
The company relies on a small senior management team and three-person technical staff with specialized knowledge; loss of these individuals could disrupt operations, damage customer relationships, and cost significant time and money to replace.
Source
“Our success depends significantly on the continued service of our senior management, as well as our three person technical and R&D staff”
High confidenceView in filing → - Hazardous Chemical Operations Risk
The company handles highly toxic, corrosive, or temperature-sensitive chemicals, and accidents could cause injuries, fatalities, environmental contamination, property damage, regulatory penalties, and facility shutdowns.
Source
“Despite our safety protocols and quality control measures, accidents can occur that could result in: Fires, explosions, or chemical releases that could cause injuries or fatalities to our employees or nearby communities”
High confidenceView in filing → - Immediate Dilution and No Prior Trading Market
Investors purchasing Class A Common Stock will experience immediate and substantial dilution above net tangible book value, and no active trading market previously existed, meaning the stock price could be highly volatile or decline below the IPO price.
Source
“The initial public offering price of our Class A Common Stock is substantially higher than the (as adjusted) net tangible book value per share of our Class A Common Stock.”
High confidenceView in filing →
Underwriters
The banks running the offering, from the filing. Informational only — not a recommendation or where to buy.
Underwriters allocate IPO shares primarily to their institutional and wealth-management clients; a directed share program (when present) reserves shares for company insiders/affiliates, not the general public. Not investment advice.
Source
“subject to certain limited exceptions and waiver by R.F. Lafferty & Co., Inc., as representative of the underwriters.”